Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...
Bibliographic Details
| Authors: |
Almeida AM,
Prebet T,
Itzykson R,
Ramos F,
Al-Ali H,
Shammo J,
Pinto R,
Maurillo L,
Wetzel J,
Musto P,
Van De Loosdrecht AA,
Costa MJ,
Esteves S,
Burgstaller S,
Stauder R,
Autzinger EM,
Lang A,
Krippl P,
Geissler D,
Falantes JF,
Pedro C,
Bargay J,
Deben G,
Garrido A,
Bonanad S,
Diez-Campelo M,
Thepot S,
Ades L,
Sperr WR,
Valent P,
Fenaux P,
Sekeres MA,
Greil R,
Pleyer L |
|---|
| Format: | article
|
|---|
| Status: | Published version |
|---|
| Publication Date: | 2017 |
|---|
| Country: | España |
|---|
| Institution: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
|---|
| Repository: | r-FISABIO. Repositorio Institucional de Producción Científica |
|---|
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p3381 |
|---|
| Online Access: | https://fisabio.portalinvestigacion.com/publicaciones/3381
|
|---|
| Access Level: | Open access |
|---|
| Keyword: | acute erythroleukemia, azacitidine, decitabine |
|---|
